ストックスクリーナーアプリを入手
1.54
0.96%
-0.03
Enlivex Therapeutics Ltd (ENLV) 最新ニュース
ENLV’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation - Simply Wall St
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy - Yahoo Finance
Enlivex Announces 2024 Shareholder Meeting - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at HC Wainwright - Defense World
Enlivex stock poised for growth with key trial readouts by 2025, says H.C. Wainwright - Investing.com India
Enlivex Therapeutics Financials Indicate Net Loss - TipRanks
Enlivex Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - StockTitan
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance
Enlivex shares rise on EF Hutton's Buy rating By Investing.com - Investing.com Australia
Enlivex shares rise on EF Hutton's Buy rating - Investing.com India
Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 1.9% - Defense World
Enlivex Advances Psoriatic Arthritis Treatment with Allocetra™ - TipRanks
Enlivex Receives Regulatory Authorization For The - GlobeNewswire
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis - StockTitan
Enlivex Therapeutics and Biotricity Interviews to Air on the Red - WICZ
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent - openPR
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV) - Barchart
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent - WICZ
Enlivex Therapeutics (NASDAQ:ENLV) Trading 0.6% Higher - Defense World
Enlivex Commences Key Trial for Thumb Osteoarthritis - TipRanks
Enlivex Announces the Dosing of the First Patient in a - GlobeNewswire
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating ... - Yahoo Finance
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis - Yahoo Finance
Enlivex Therapeutics Ltd expected to post a loss of 22 cents a shareEarnings Preview - XM
Enlivex Webinar to Discuss Breakthrough Immunotherapy - TipRanks
Join Enlivex Therapeutics' Chief Executive Officer for a - GlobeNewswire
Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 - Yahoo Finance
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 - Yahoo Finance
Where Do Analysts Think The Enlivex Therapeutics Ltd (NASDAQ: ENLV) Is Going – Stocks Register - Stocks Register
Enlivex Therapeutics Ltd [ENLV] Is Currently -7.19 below its 200 Period Moving Avg: What Does This Mean? – The ... - The DBT News
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee ... - Markets Insider
Enlivex’s Allocetra Shows Promise in Osteoarthritis Trial - TipRanks
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee ... - GlobeNewswire
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee ... - StockTitan
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis - Yahoo Finance
Enlivex Therapeutics Reports Q1 FinancialsTipRanks.com - TipRanks
Reviewing Enlivex Therapeutics (NASDAQ:ENLV) and 180 Life Sciences (NASDAQ:ATNF) - Defense World
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Forecasted to Post Q1 2025 Earnings of ($0.16) Per Share - Defense World
Enlivex Therapeutics (NASDAQ:ENLV) Price Target Cut to $6.00 by Analysts at HC Wainwright - Defense World
Yet Another Biotech Stock Has Found Success During Tuesday's Session - MSN
Enlivex Advances Trial for Thumb Osteoarthritis TherapyTipRanks.com - TipRanks
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra ... - GlobeNewswire
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra ... - Yahoo Finance
Ratios Reveal: Breaking Down Enlivex Therapeutics Ltd (ENLV)'s Financial Health – DWinneX - The Dwinnex
Enlivex Therapeutics Announces New Securities Deal - TipRanks
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering - GlobeNewswire
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering - GlobeNewswire Inc.
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering - Yahoo Finance
Enlivex secures $5 million in direct offering, eyes more funds By Investing.com - Investing.com
Enlivex Announces $15 Million Funding PotentialTipRanks.com - TipRanks
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering - GlobeNewswire
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering - GlobeNewswire Inc.
We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate - Yahoo Finance UK
Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 0.7% - Defense World
Israel's Enlivex reports positive results in COVID-19 drug trial - Yahoo Singapore News
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events - Yahoo Finance
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in ... - Yahoo Finance
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis - GlobeNewswire Inc.
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis - Yahoo Finance
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why - Zacks Investment Research
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why - Yahoo Finance
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Enlivex reports positive data from Phase II sepsis treatment trial - Clinical Trials Arena
Nasdaq Jumps 250 Points; Crude Oil Down 1% - Benzinga
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis - GlobeNewswire Inc.
1.25%
1.76%
大文字化:
|
ボリューム (24 時間):